Glaukos Corporation
GKOS
Rang in aandelen
#2037
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Aandeelprijs
$173.09
Marktkapitalisatie
$10.21B
Verandering (1 dag)
3.78%
Verandering (1 jaar)
117.81%
Land
US
Handel Glaukos Corporation (GKOS)
Categorie
Healthcare
Winst voor Glaukos Corporation (GKOS)
Winst in Jun 2026 TTM: $-192.83M
Volgens de meest recente financiële verslagen van Glaukos Corporation bedraagt de huidige winst van het bedrijf $-192.83M. In 2023 behaalde het bedrijf een winst van $-133.73M, een daling ten opzichte van de winst van 2022, die $-98.43M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Glaukos Corporation van 2012 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-192.83M | 32.44% |
| 2024 | $-145.60M | 8.88% |
| 2023 | $-133.73M | 35.86% |
| 2022 | $-98.43M | 99.79% |
| 2021 | $-49.27M | -62.77% |
| 2020 | $-132.31M | 164.44% |
| 2019 | $-50.04M | 304.56% |
| 2018 | $-12.37M | -1,236,900.00% |
| 2017 | $1.00K | -99.98% |
| 2016 | $4.57M | -111.92% |
| 2015 | $-38.29M | 172.73% |
| 2014 | $-14.04M | -1.28% |
| 2013 | $-14.22M | -35.41% |
| 2012 | $-22.02M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $7.51B | -3,995.08% |
US
|
|
| $5.56B | -2,984.88% |
IE
|
|
| $5.15B | -2,769.67% |
US
|
|
| $3.86B | -2,102.25% |
US
|
|
| - | - |
DE
|
